Page 238 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

daunorubicin is a potential therapeutic drug against SARS-CoV-2 [46]. In this study, candidate drugs

that interacted with overlapped DEGs were identified, and the top 10 drugs with the most significant

potential were lanatoside C, digoxin, GW-8510, doxorubicin, daunorubicin, proscillaridin,
anisomycin, helveticoside, ouabain, and bisacodyl. Thus, these drugs may offer novel options for

improving COVID-19 and asthma treatment.
However, this study has some limitations. First, the data used in this study were downloaded

from a public database, and more relevant experiments should be conducted to validate the identified

hub genes and drugs. Second, further studies should be conducted to analyze the detailed

mechanisms of FOXC1, GATA2, hsa-miR-93-5p, and hsa-miR-17-5p in the progression of COVID-

19/asthma. Third, clinical evidence is required to support the targets and drugs identified in this

study.

5. Conclusions

This study identified potential biomarkers for COVID-19 and asthma and predicted druggable

targets against COVID-19/asthma comorbidity. Thus, this study provides a novel clarification of

COVID-19/asthma comorbidity treatment.

6. Statements & Declarations

Acknowledgments We acknowledge the GEO database for providing its platform and the

contributors for uploading their valuable datasets.
Funding The authors declare that no funds, grants, or other supports have been received during the

preparation of this manuscript.

Conflict of Interest The authors have no relevant financial or non-financial interests to disclose.

Author Contributions All authors contributed to the study conception and design. All authors read

and approved the final version of the manuscript.

Data availability The datasets generated and/or analyzed in the current study are available in the

GEO (https://www.ncbi.nlm.nih.gov/geo/) database.

Ethics Approval Ethics approval was waived for this study because all the analyses performed in

this study were based on open-source data from public databases.

Consent to Participate Not applicable.

Consent to Publish Not applicable.

- 233 -